Upcoming Events All Events

Latest News

KONICA MINOLTA BUSINESS SOLUTIONS U.S.A., INC: Konica Minolta’s Workplace Hub Awarded Managed.IT Magazine’s Editor’s Choice

Konica Minolta Business Solutions, U.S.A., Inc. is proud to announce that its Workplace Hub solution recently received the prestigious Editor’s Choice award by Managed.IT Magazine.

MIDDLESEX COUNTY REGIONAL CHAMBER OF COMMERCE: Jessica Schwartz and Adam Livow are just two of many individuals who help represent iPlay America in freehold

Jessica Schwartz, Vice President Sales & Marketing of iPlay America, and Adam Livow, Executive Chef at iPlay America, are proud employees of the iPlay America family in Freehold.

MIDDLESEX COUNTY REGIONAL CHAMBER OF COMMERCE: Be A Part of April's Networking Breakfast

Don’t miss our April Networking Breakfast, Friday, April 26 at 8:30 a.m., at one of the most well-known restaurants in the Hub City, Due Mari, 78 Albany St., New Brunswick.

KONICA MINOLTA BUSINESS SOLUTIONS U.S.A., INC: Konica Minolta To Exhibit As Gold Sponsor At ALA 2019

Konica Minolta Business Solutions U.S.A., Inc. (Konica Minolta) and its IT Services Division, All Covered, today announced their gold sponsorship and participation in the Association of Legal Administrators (ALA) 2019 Annual Conference & Expo in Grapevine, Texas, April 14-17.

CELGENE CORPORATION: Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Biologics License Application to U.S. FDA

Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that Celgene has submitted a Biologics License Application (BLA) for luspatercept, an erythroid maturation agent, for the treatment of adult patients with very low to intermediate risk myelodysplastic syndromes (MDS)-associated anemia who have ring sideroblasts and require red blood cell (RBC) transfusions and for the treatment of adult patients with beta-thalassemia-associated anemia who require RBC transfusions.

DAIICHI SANKYO, INC: EMA Validates Daiichi Sankyo’s Marketing Authorization Application for Pexidartinib for Treatment of Patients with TGCT, a Rare, Debilitating, Non-Malignant Tumor

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the European Medicines Agency (EMA) validated the Marketing Authorization Application (MAA) for pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT), which is associated with severe morbidity or functional limitations, and which is not amenable to improvement with surgery.

Metro Business Network